- Home
- CLDI vs RLMD Comparison
CLDI vs RLMD Comparison
Compare CLDI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- RLMD
- Stock Information
- Founded
- CLDI 2014
- RLMD 2004
- Country
- CLDI United States
- RLMD United States
- Employees
- CLDI N/A
- RLMD N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- RLMD Health Care
- Exchange
- CLDI Nasdaq
- RLMD Nasdaq
- Market Cap
- CLDI 20.2M
- RLMD 20.3M
- IPO Year
- CLDI N/A
- RLMD N/A
- Fundamental
- Price
- CLDI $0.59
- RLMD $0.59
- Analyst Decision
- CLDI
- RLMD Buy
- Analyst Count
- CLDI 0
- RLMD 3
- Target Price
- CLDI N/A
- RLMD $5.00
- AVG Volume (30 Days)
- CLDI 51.3M
- RLMD 206.5K
- Earning Date
- CLDI 08-12-2025
- RLMD 08-07-2025
- Dividend Yield
- CLDI N/A
- RLMD N/A
- EPS Growth
- CLDI N/A
- RLMD N/A
- EPS
- CLDI N/A
- RLMD N/A
- Revenue
- CLDI N/A
- RLMD N/A
- Revenue This Year
- CLDI N/A
- RLMD N/A
- Revenue Next Year
- CLDI N/A
- RLMD N/A
- P/E Ratio
- CLDI N/A
- RLMD N/A
- Revenue Growth
- CLDI N/A
- RLMD N/A
- 52 Week Low
- CLDI $0.20
- RLMD $0.24
- 52 Week High
- CLDI $3.89
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- CLDI 51.83
- RLMD 44.70
- Support Level
- CLDI $0.56
- RLMD $0.60
- Resistance Level
- CLDI $0.91
- RLMD $0.67
- Average True Range (ATR)
- CLDI 0.10
- RLMD 0.06
- MACD
- CLDI -0.02
- RLMD -0.00
- Stochastic Oscillator
- CLDI 27.34
- RLMD 16.42
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.